Program
remdesivir
Also written as “Remdesivir”, “Remdesivir (RDV)” and “RDV”.
Its studies are mostly in COVID-19, led by 4 companies.
Furthest: phase 3, since Feb 28, 20209 company-led studies, 1 open or runningNext primary completion: Sep 28, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 60 open or running | phase 3since Feb 28, 2020 | Feb 28, 2020 | none ahead |
| Biomed Industries | 10 open or running | phase 1since Jul 13, 2020 | Jul 13, 2020 | none ahead |
| Dr. Md. Alimur Reza | 10 open or running | phase 2since Oct 20, 2020 | Oct 20, 2020 | none ahead |
| Pfizer | 11 open or running | phase 3since May 5, 2025 | May 5, 2025 | Sep 28, 2027phase 3 · NCT07013474 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 28, 2020First studies: 2 phase 3 studies in COVID-19New to Gilead SciencesGilead Sciences · NCT04292899, NCT04292730
- Jun 8, 2020Phase 3 study in COVID-19Gilead Sciences · NCT04431453 · 59 enrolled · United States, Italy, Spain and more
- Jul 13, 2020Biomed Industries's first study: phase 1 study in COVID-19New to Biomed IndustriesBiomed Industries · NCT04480333 · 45 enrolled · United States
- Aug 5, 2020Phase 3 study in COVID-19Gilead Sciences · NCT04501952 · 584 enrolled · United States, Denmark, Spain and more
- Aug 26, 2020Phase 2 study in COVID-19Gilead Sciences · NCT04539262 · 156 enrolled · United States
- Oct 20, 2020Dr. Md. Alimur Reza's first study: phase 2 study in COVID-19New to Dr. Md. Alimur RezaDr. Md. Alimur Reza · NCT04596839 · 60 enrolled · Bangladesh
- Feb 8, 2021Phase 3 study in COVID-19Gilead Sciences · NCT04745351 · 249 enrolled · United States, Brazil, Portugal and more
- May 5, 2025Pfizer's first study: phase 3 study in COVID-19New to PfizerPfizer · NCT07013474 · 300 planned · United States, Argentina, Belgium and more
Ahead
- Sep 28, 2027Primary completion: phase 3 study in COVID-19Pfizer · NCT07013474
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“RNA-directed RNA polymerase L inhibitor; Replicase polyprotein 1ab inhibitor”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07013474COVID-19 · United States, Argentina, Belgium and more | 3 | Recruiting | Pfizer | Sep 28, 2027 | 300 |
| NCT04745351COVID-19 · United States, Brazil, Portugal and more | 3 | Terminated | Gilead Sciences | Apr 20, 2022 | 249 |
| NCT04596839COVID-19 · Bangladesh | 2 | Completed | Dr. Md. Alimur Reza | Apr 30, 2021 | 60 |
| NCT04539262COVID-19 · United States | 2 | Completed | Gilead Sciences | Feb 26, 2021 | 156 |
| NCT04501952COVID-19 · United States, Denmark, Spain and more | 3 | Terminated | Gilead Sciences | May 6, 2021 | 584 |
| NCT04480333COVID-19 · United States | 1 | UNKNOWN | Biomed Industries | Dec 31, 2020 | 45 |
| NCT04431453COVID-19 · United States, Italy, Spain and more | 3 | Completed | Gilead Sciences | Feb 10, 2023 | 59 |
| NCT04292899COVID-19 · United States, China, France and more | 3 | Completed | Gilead Sciences | Apr 9, 2020 | 4,891 |
| NCT04292730COVID-19 · United States, China, France and more | 3 | Completed | Gilead Sciences | Apr 29, 2020 | 1,113 |
How it is read
Names in the registry
- “Remdesivir”, 5 entries
- “remdesivir”, 1 entry
- “Remdesivir (RDV)”, 1 entry
- “RDV”, 1 entry
- “Drug: GS-5734 - 1.00 mg/kg”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.